HK Stock Market Move | AKESO (09926) up another 4%, the company's first triple-criticism AK150 recently received clinical approval.
Kangfang Biology (09926) increased by over 4% again, as of the time of the press release, up 4.26%, at HK$114.9, with a turnover of HK$529 million.
AKESO (09926) rose by over 4%, as of the time of writing, it was up 4.26% at 114.9 Hong Kong dollars, with a trading volume of 529 million Hong Kong dollars.
In terms of news, recently, AKESO announced that its three specific monoclonal antibody new drug AK150 has obtained the NMPA clinical trial implied approval for the treatment of advanced malignant solid tumors. AK150 is a globally innovative ILT2/ILT4/CSF1R triple antibody developed by AKESO based on AI pharmaceutical research technology platform and Tetrabody multispecific antibody technology platform, and is also AKESO's first triple antibody new drug to enter clinical stage.
Related Articles
KB LAMINATES (01888) will distribute a special dividend of HK$0.28 per share on July 7th.
KB LAMINATES (01888) will distribute a final dividend of HK$0.25 per share on July 7th.
KB LAMINATES (01888) announces annual performance, with a net profit attributable to shareholders of HK$2.442 billion, an increase of 84.16% year-on-year.
KB LAMINATES (01888) will distribute a special dividend of HK$0.28 per share on July 7th.
KB LAMINATES (01888) will distribute a final dividend of HK$0.25 per share on July 7th.
KB LAMINATES (01888) announces annual performance, with a net profit attributable to shareholders of HK$2.442 billion, an increase of 84.16% year-on-year.
